• Je něco špatně v tomto záznamu ?

Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity

M. Izquierdo, D. Lin, S. O'Neill, LA. Webster, C. Paterson, J. Thomas, ME. Aguado, E. Colina Araújo, D. Alpízar-Pedraza, H. Joji, L. MacLean, A. Hope, DW. Gray, M. Zoltner, MC. Field, J. González-Bacerio, M. De Rycker

. 2024 ; 18 (2) : e0011956. [pub] 20240215

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007118

Grantová podpora
Wellcome Trust - United Kingdom

BACKGROUND: Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and leads to ~10,000 deaths each year. Nifurtimox and benznidazole are the only two drugs available but have significant adverse effects and limited efficacy. New chemotherapeutic agents are urgently required. Here we identified inhibitors of the acidic M17 leucyl-aminopeptidase from T. cruzi (LAPTc) that show promise as novel starting points for Chagas disease drug discovery. METHODOLOGY/PRINCIPAL FINDINGS: A RapidFire-MS screen with a protease-focused compound library identified novel LAPTc inhibitors. Twenty-eight hits were progressed to the dose-response studies, from which 12 molecules inhibited LAPTc with IC50 < 34 μM. Of these, compound 4 was the most potent hit and mode of inhibition studies indicate that compound 4 is a competitive LAPTc inhibitor, with Ki 0.27 μM. Compound 4 is selective with respect to human LAP3, showing a selectivity index of >500. Compound 4 exhibited sub-micromolar activity against intracellular T. cruzi amastigotes, and while the selectivity-window against the host cells was narrow, no toxicity was observed for un-infected HepG2 cells. In silico modelling of the LAPTc-compound 4 interaction is consistent with the competitive mode of inhibition. Molecular dynamics simulations reproduce the experimental binding strength (-8.95 kcal/mol), and indicate a binding mode based mainly on hydrophobic interactions with active site residues without metal cation coordination. CONCLUSIONS/SIGNIFICANCE: Our data indicates that these new LAPTc inhibitors should be considered for further development as antiparasitic agents for the treatment of Chagas disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007118
003      
CZ-PrNML
005      
20240423155732.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pntd.0011956 $2 doi
035    __
$a (PubMed)38359089
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Izquierdo, Maikel $u Centre for Protein Studies, Faculty of Biology, University of Havana, La Habana, Cuba
245    10
$a Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity / $c M. Izquierdo, D. Lin, S. O'Neill, LA. Webster, C. Paterson, J. Thomas, ME. Aguado, E. Colina Araújo, D. Alpízar-Pedraza, H. Joji, L. MacLean, A. Hope, DW. Gray, M. Zoltner, MC. Field, J. González-Bacerio, M. De Rycker
520    9_
$a BACKGROUND: Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and leads to ~10,000 deaths each year. Nifurtimox and benznidazole are the only two drugs available but have significant adverse effects and limited efficacy. New chemotherapeutic agents are urgently required. Here we identified inhibitors of the acidic M17 leucyl-aminopeptidase from T. cruzi (LAPTc) that show promise as novel starting points for Chagas disease drug discovery. METHODOLOGY/PRINCIPAL FINDINGS: A RapidFire-MS screen with a protease-focused compound library identified novel LAPTc inhibitors. Twenty-eight hits were progressed to the dose-response studies, from which 12 molecules inhibited LAPTc with IC50 < 34 μM. Of these, compound 4 was the most potent hit and mode of inhibition studies indicate that compound 4 is a competitive LAPTc inhibitor, with Ki 0.27 μM. Compound 4 is selective with respect to human LAP3, showing a selectivity index of >500. Compound 4 exhibited sub-micromolar activity against intracellular T. cruzi amastigotes, and while the selectivity-window against the host cells was narrow, no toxicity was observed for un-infected HepG2 cells. In silico modelling of the LAPTc-compound 4 interaction is consistent with the competitive mode of inhibition. Molecular dynamics simulations reproduce the experimental binding strength (-8.95 kcal/mol), and indicate a binding mode based mainly on hydrophobic interactions with active site residues without metal cation coordination. CONCLUSIONS/SIGNIFICANCE: Our data indicates that these new LAPTc inhibitors should be considered for further development as antiparasitic agents for the treatment of Chagas disease.
650    _2
$a lidé $7 D006801
650    _2
$a leucylaminopeptidasa $x chemie $x farmakologie $x terapeutické užití $7 D007931
650    12
$a Trypanosoma cruzi $7 D014349
650    12
$a Chagasova nemoc $x farmakoterapie $7 D014355
650    _2
$a objevování léků $7 D055808
650    _2
$a antiparazitární látky $x terapeutické užití $7 D000977
650    12
$a trypanocidální látky $x terapeutické užití $7 D014344
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lin, De $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom
700    1_
$a O'Neill, Sandra $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom
700    1_
$a Webster, Lauren A $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom
700    1_
$a Paterson, Christy $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom
700    1_
$a Thomas, John $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom
700    1_
$a Aguado, Mirtha Elisa $u Centre for Protein Studies, Faculty of Biology, University of Havana, La Habana, Cuba
700    1_
$a Colina Araújo, Enrique $u Department of Biochemistry, Faculty of Biology, University of Havana, La Habana, Cuba
700    1_
$a Alpízar-Pedraza, Daniel $u Centre for Pharmaceuticals Research and Development, La Habana, Cuba
700    1_
$a Joji, Halimatu $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom
700    1_
$a MacLean, Lorna $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom
700    1_
$a Hope, Anthony $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom
700    1_
$a Gray, David W $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom
700    1_
$a Zoltner, Martin $u Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, United Kingdom $u Department of Parasitology, Faculty of Science, Charles University in Prague, Biocev, Vestec, Czech Republic
700    1_
$a Field, Mark C $u School of Life Sciences, University of Dundee, Dundee, United Kingdom $u Biology Centre, Czech Academy of Sciences, Institute of Parasitology, České Budějovice, Czech Republic
700    1_
$a González-Bacerio, Jorge $u Centre for Protein Studies, Faculty of Biology, University of Havana, La Habana, Cuba $u Department of Biochemistry, Faculty of Biology, University of Havana, La Habana, Cuba
700    1_
$a De Rycker, Manu $u Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, Dundee, United Kingdom $1 https://orcid.org/0000000231713519
773    0_
$w MED00165375 $t PLoS neglected tropical diseases $x 1935-2735 $g Roč. 18, č. 2 (2024), s. e0011956
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38359089 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155729 $b ABA008
999    __
$a ok $b bmc $g 2081236 $s 1216885
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 18 $c 2 $d e0011956 $e 20240215 $i 1935-2735 $m PLoS neglected tropical diseases $n PLoS negl. trop. dis. $x MED00165375
GRA    __
$p Wellcome Trust $2 United Kingdom
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace